InMed Pharmaceuticals Inc.(INM)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

InMed Pharmaceuticals Inc. (INM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INM at 20.9/100 on a 32-signal composite quality model, placing it at rank #2,771 of 2,960 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INM by reported 13-F value include ADAR1 Capital Management, Vivo Capital, Squadron Capital Management, based on the most recent SEC filings. INM trades on the Nasdaq exchange and files with the SEC under CIK 1728328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InMed Pharmaceuticals Inc. directly from SEC EDGAR.

AI Quality Score

20.9/100

AI Rank

#2,771

Net Income

$-5.8M

INM key financials by period

InMed Pharmaceuticals Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$4.9M$-8.2M-175.8%
FY 202410-K$4.6M$-7.7M-166.8%
FY 202310-K$4.1M$-7.9M-192.2%
FY 202210-K$1.1M$-18.6M—
FY 202110-K$1.9M$-10.2M—

Institutions holding INM

Institutional investors reporting a position in InMed Pharmaceuticals Inc. on SEC Form 13F.
InstitutionSharesValueReported
ADAR1 Capital Management800,000$1.2M2026-06-30
Vivo Capital798,377$1.2M2026-06-30
Squadron Capital Management325,000$503.8K2026-06-30
Ikarian Capital245,025$379.8K2026-06-30
Ursa Fund Management125,800$195.0K2026-06-30
SUVRETTA CAPITAL MANAGEMENT100,000$155.0K2026-06-30
BOOTHBAY FUND MANAGEMENT74,244$115.1K2026-06-30
SABBY MANAGEMENT44,970$69.7K2026-06-30
JANE STREET GROUP43,078$66.8K2026-06-30
VR Adviser32,685$50.7K2026-06-30
SEC EDGAR: CIK 1728328 →
INM

InMed Pharmaceuticals Inc.

INM
NasdaqSmall CapHealthcare

13F Pro Quality Score

20.9/100

Rank #2,771 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-5.84M

EPS (Diluted)

Q2 2026
EDGAR

$-1.43

Top Institutional Holders

as of Q2 2026
$4.18M total
ADAR1 Capital Management, LLC
$1.24MNew
Vivo Capital, LLC
$1.24MNew
Squadron Capital Management LLC
$503.8KNew
Ikarian Capital, LLC
$379.8KNew
Ursa Fund Management, LLC
$195.0KNew
SUVRETTA CAPITAL MANAGEMENT, LLC
$155.0KNew
BOOTHBAY FUND MANAGEMENT, LLC
$115.1KNew
SABBY MANAGEMENT, LLC
$69.7K-79.6%
JANE STREET GROUP, LLC
$66.8KNew
VR Adviser, LLC
$50.7KNew

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…